

**Ayerst Laboratories—Cont.**

Compulsory licensing, effect, 11:7; 15:32  
 Premarin, development, 12:11  
 Princeton, N.J. move, 8:61; 10:6; 11:11; 15:39  
 Research and development, costs, 12:10

**Baby boom** *see* Drugs and pharmaceuticals industry—Growth

**Barrett, B.P.** (Canadian Chamber of Commerce)  
 Patent Act (amdt.)(Bill C-22), 8:3, 17-8, 25, 27

**Batterson, Leslie** (National Pensioners and Senior Citizens Federation)  
 Patent Act (amdt.)(Bill C-22), 8:4, 58-9, 68

**Beachell, Laurey** (Coalition of Provincial Organizations of the Handicapped)  
 Patent Act (amdt.)(Bill C-22), 15:3, 71-85

**Bean, D.T.** (Public Service Alliance of Canada)  
 Patent Act (amdt.)(Bill C-22), 10:3, 20-33

**Bergeron, Michel** (Canadian Society for Clinical Investigation)  
 Patent Act (amdt.)(Bill C-22), 12:3, 30-2, 37-8, 40-2

**Bertrand, Gabrielle** (PC—Brome—Missisquoi; Parliamentary Secretary to Minister of Consumer and Corporate Affairs)  
 Bio-medical research, 10:43-4  
 Brain drain, 10:11; 13:45  
 Brand name drugs, 3:70; 5:25-6; 7:16-7; 9:20; 10:45; 13:15; 15:26  
 Canadian Health Coalition, 7:17  
 Cystic fibrosis, 9:20-1  
 Drug Prices Review Board, 3:71; 5:25; 10:45; 13:15-6; 15:27  
 Drugs and pharmaceuticals, 3:70; 15:39  
 Drugs and pharmaceuticals industry, 10:11; 13:46  
 Generic drugs, 3:33-4; 15:65  
 Health care, 15:26  
 Intellectual property, 10:11  
 Kidney Foundation of Canada, 13:14-5  
 Patent Act (amdt.)(Bill C-22), 1:36, 42; 3:33-4, 70-2; 4:11, 21; 5:25-6; 6:44-5; 7:16-7; 9:20-1, 43, 52; 10:10-2, 43-5; 13:10, 14-6, 45-6; 15:26-7, 39-40, 65-6; 16:12-3; 17:18, 25, 29-30, 39-40  
 Pharmacists, 15:39-40  
 Procedure and Committee business  
 Bills, 16:12-3  
 Corrigendum, Ms., 17:18  
 Meetings, 1:42  
 Witnesses, M. (White), 4:11, 21  
 Quebec Federation of Senior Citizens, 1:36; 15:66  
 Senior citizens, 1:36; 15:65  
 Universities, 6:44-5

**Best, Robert** (Consumers Association of Canada)  
 Patent Act (amdt.)(Bill C-22), 6:3, 28

**Bigsby, Stephen** (Montreal Board of Trade)  
 Patent Act (amdt.)(Bill C-22), 10:3, 7-19

**Bill C-91** *see* Competition Tribunal Act**Bio-medical research**

Benefits, industry information tabling, 10:36-7  
 Employment prospects, brain drain, etc., 10:35, 38, 46  
 Government funding, 10:34, 40-1, 45-6; 15:47  
 Legislation, Bill C-22 benefits, 10:38, 43-4  
 Need, 10:35-6  
 Technology transfer, 10:35

**Bio-mega Inc.** *see* Witnesses

**Biomira** *see* Witnesses

**Biotech, 1:45****Biotechnology**

Defining, 12:45-6

**Biotechnology industry, 12:14; 17:49**

Canadian ownership, 8:38-9  
 Competitive advantage, geographic location, etc., 12:52-3  
 Compulsory licensing, effect, 12:43, 46  
 Employment opportunities, 12:43-4  
 Funding, need, government cut-backs, brain drain phenomenon, etc., 8:34, 51-2, 54-5; 12:47-8, 52-3  
 Legislation, Bill C-22 impact, 3:8, 11; 11:40; 12:46, 53  
 Process patents affecting, Interleuken 2 example, United States/United Kingdom comparison, etc., 8:35-42, 44-6, 48-9, 52, 56, 58; 11:12-3; 12:15  
 Licensing arrangements, agreements, etc., 8:57  
 New Democratic Party position, 1:24  
 Patent law principles, "special case" exemption, etc., 8:46-7, 51; 12:14-6, 51  
 United States Supreme Court decision, 12:15  
 Research and development  
 Clinical/basic research mix, 10:44  
 Recombinant DNA research/fermentation, etc., importance, 12:51-2  
 Unions, funding, 12:16  
 Stimulating, growth, 1:24, 27, 30; 12:15  
 Brossard report, 12:32  
 Venture capitalists' role, 8:44-5, 50, 53  
*See also* Drugs and pharmaceuticals industry—Montreal, Que.

**Birch, G.A. Sandy** (Committee Clerk)

Procedure and Committee business, organization meeting, 1:6  
 References, 12:76

**Blue Cross** *see* Drug plans

**Boehringer Ingelheim**

Research centre closing, Quebec, 10:12

**Boots Drug Stores, 1:27**

Background, 6:74

**Boulder, Colorado** *see* High technology centres

**Bowie, William** (Canadian Infectious Disease Society)

Patent Act (amdt.)(Bill C-22), 15:3, 5-17

**Brain drain, 10:11**

Compulsory licensing, promoting, effect, etc., 7:13-4; 11:47; 12:18; 13:45-6

*See also* Bio-medical research—Employment prospects; Biotechnology industry—Funding; Pharmacists; Universities

**Branch plants** *see* Automotive industry

**Brand name drugs**

Availability in Canada, Alzheimer's drug example, etc., 3:23-4, 61-2; 10:15, 32-3; 11:50-1; 12:74-6; 15:55  
 Supply problems, potential, 9:45  
 Drug Prices Review Board, effect, 3:72; 7:5  
 Exclusivity period from imports, new drugs, 10 year patent protection, Bill C-22 proposing, 1:12, 18-20; 5:11, 30; 6:6, 49; 8:59; 9:25; 14:14, 42-3, 54, 60, 62, 70-1; 15:9-10, 30, 37, 60  
 Canadian companies stimulating, 1:20; 3:32-3, 47; 5:12  
 China, comparison, 3:61  
 Compulsory licensing exemption, revoking, etc., 5:11-2, 14; 7:6; 10:22; 16:23, 25  
*See also* Brand name drugs—Research and development record